|
EP3101122B1
(en)
|
2009-08-24 |
2023-06-14 |
Baylor College of Medicine |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US8809050B2
(en)
|
2009-12-08 |
2014-08-19 |
Wilson Wolf Manufacturing |
Methods of cell culture for adoptive cell therapy
|
|
WO2012129201A1
(en)
*
|
2011-03-22 |
2012-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
CN104769104A
(zh)
|
2011-12-12 |
2015-07-08 |
细胞药物有限公司 |
扩大t细胞的方法
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
PT2812431T
(pt)
|
2012-02-09 |
2019-10-18 |
Baylor College Medicine |
Pepmixes para gerar ctls multivirais com larga especifidade
|
|
SG11201407226WA
(en)
*
|
2012-05-18 |
2014-12-30 |
Wolf Wilson Mfg Corp |
Improved methods of cell culture for adoptive cell therapy
|
|
CN104411819B
(zh)
*
|
2012-06-11 |
2019-05-10 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
CN118562610A
(zh)
*
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
CN105593362B
(zh)
|
2013-09-23 |
2021-09-10 |
威尔逊沃夫制造公司 |
遗传修饰动物细胞的改进方法
|
|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
JP6999941B2
(ja)
|
2015-09-18 |
2022-02-10 |
ベイラー カレッジ オブ メディスン |
病原体からの免疫原性抗原同定および臨床的有効性との相関
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
CN105418766A
(zh)
*
|
2015-12-22 |
2016-03-23 |
深圳市北科生物科技有限公司 |
一种用于免疫治疗的eb病毒lmp2a串联表位肽及其应用
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
US10052372B2
(en)
*
|
2016-05-24 |
2018-08-21 |
Tessa Therapeutics Pte Ltd |
T cell expansion
|
|
CN109843921B
(zh)
|
2016-07-07 |
2023-05-26 |
艾欧凡斯生物治疗公司 |
程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US11401507B2
(en)
*
|
2016-11-17 |
2022-08-02 |
Iovance Biotherapeutics, Inc. |
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
|
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
WO2018195014A1
(en)
|
2017-04-19 |
2018-10-25 |
Neubiser Richard |
Bioreactor for biological material
|
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
EP4501408A3
(en)
|
2017-11-17 |
2025-04-09 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
SG11202006541UA
(en)
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
MA52667B1
(fr)
|
2018-03-29 |
2024-07-31 |
Iovance Biotherapeutics, Inc. |
Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
CA3112599A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
US20230039976A1
(en)
|
2018-11-05 |
2023-02-09 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
|
|
JP7710372B2
(ja)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
AU2021217003A1
(en)
|
2020-02-04 |
2022-09-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-dinitrophenol chimeric antigen receptors
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
TW202208616A
(zh)
|
2020-05-04 |
2022-03-01 |
美商艾歐凡斯生物治療公司 |
改良之腫瘤反應性ｔ細胞的選擇
|
|
EP4146794A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
|
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
AU2022246174A1
(en)
|
2021-03-25 |
2023-09-14 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
EP4326287A2
(en)
|
2021-04-19 |
2024-02-28 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240342285A1
(en)
|
2021-07-28 |
2024-10-17 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4430167A1
(en)
|
2021-11-10 |
2024-09-18 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
US20250101380A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|